Bayer Set To Sew Up HCC Market As RESORCE Hits Endpoint
Executive Summary
Top-line success for Bayer's trial of Stivarga in advanced liver cancer in patients who have progressed on its other therapy Nexavar gives the company an opportunity to dominate the market, but Stivarga's potential may be overshadowed by its drawbacks and looming competition.
You may also be interested in...
Bayer Protests 'Incomprehensible' German Decision on Stivarga In mCRC
A decision by the German health technology assessment agency IQWiG that new analysis provided by Bayer of Stivarga (regorafenib) in metastatic colorectal cancer (mCRC) result in the product's disadvantages outweighing its benefits "is essentially incomprehensible to Bayer," the German pharma told Scrip.
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.